Edition:
United Kingdom

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

9.82USD
19 Jul 2019
Change (% chg)

$-0.29 (-2.87%)
Prev Close
$10.11
Open
$10.13
Day's High
$10.13
Day's Low
$9.78
Volume
285,223
Avg. Vol
296,204
52-wk High
$20.85
52-wk Low
$9.51

Summary

Name Age Since Current Position

Robert Azelby

51 2018 President, Chief Executive Officer, Director

Carlos Campoy

54 2018 Chief Financial Officer

Erin Lavelle

41 2018 Chief Operating Officer

James Bucher

53 2019 Executive Vice President, General Counsel

Randal Hassler

61 2018 Executive Vice President, Pharmaceutical Operations

Nadia Dac

49 2019 Chief Commercial Officer

Jeffrey Smith

59 2017 Managing Director of Alder BioPharmaceuticals Limited

Paul Streck

56 2019 Chief Medical Officer

Paul Cleveland

62 2018 Director

Paul Carter

58 2015 Independent Director

Jeremy Green

45 2018 Independent Director

A. Bruce Montgomery

65 2010 Independent Director

Heather Preston

53 2007 Independent Director

Clay Siegall

58 2005 Independent Director

Wendy Yarno

64 2017 Independent Director

Biographies

Name Description

Robert Azelby

Mr. Robert W. Azelby is appointed as President, Chief Executive Officer, Director of the Company effective June 13, 2018. Mr. Azelby has served as our President and Chief Executive Officer since June 2018. From November 2015 to May 2018, Mr. Azelby served as Executive Vice President, Chief Commercial Officer of Juno Therapeutics, Inc. From June 2012 to October 2015, Mr. Azelby served as Vice President and General Manager, Oncology at Amgen Inc. From October 2010 to May 2012, he served as Amgen’s Vice President, Amgen Oncology Sales. Prior to that, he served in various positions at Amgen, including periods as Vice President, Commercial Effectiveness Unit and General Manager of Amgen Netherlands. Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Cascadian Therapeutics, Inc. from April 2017 to March 2018. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School. The Nominating and Corporate Governance Committee believes that Mr. Azelby is qualified to serve on our Board of Directors due to his experience in the biopharmaceutical industry, including his operational experience and strong track record in both large and small biopharmaceutical environments.

Carlos Campoy

Mr. Carlos Campoy is Chief Financial Officer of the Company. Mr. Campoy has served as our Chief Financial Officer since December 2018. From September 2017 to December 2018, Mr. Campoy served as a partner of Think Forwards, a financial consulting firm. From March 2015 to November 2016, Mr. Campoy served as Vice President of Finance, International at Allergan plc, where he previously served as Vice President and Financial Controller, Europe, Africa and Middle East from July 2014 to March 2015. Prior to joining Allergan, Mr. Campoy had an 18-year tenure at Eli Lilly and Company, from August 1996 to July 2014, where he held a number of senior financial leadership positions of increasing responsibility, most recently serving as Chief Financial Officer, Eli Lilly Japan K.K. from January 2013 to July 2014. Mr. Campoy is a Certified Management Accountant (CMA). He holds an M.B.A. in Finance and Decision Information Systems from Indiana University and a B.S. in Management from Faculdade C.C. Administracao de Tupa, Tupa in São Paulo, Brazil.

Erin Lavelle

Ms. Erin Lavelle is Chief Operating Officer of the Company. Ms. Lavelle has served as our Chief Operating Officer since April 2018. From October 2017 to March 2018, Ms. Lavelle served as the General Manager of the Taiwan affiliate of Amgen Inc., a biopharmaceutical company. From June 2016 to September 2017, Ms. Lavelle served as Executive Director, Japan and Asia-Pacific Commercial Excellence and Digital Health at Amgen. From July 2003 to June 2016, Ms. Lavelle served in roles of increasing responsibility at Amgen, including as Executive Director in the areas of Global Marketing; Global Commercial Finance; and Strategy and Corporate Development. She began her career in 1998 as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle holds a B.A. in Economics from Yale University.

James Bucher

Mr. James B. Bucher, J.D., is Executive Vice President, General Counsel of the Company. Mr. Bucher has served as our Executive Vice President and General Counsel since February 2019 and served as our Senior Vice President and General Counsel from January 2016 to February 2019. During 2015, Mr. Bucher served as a consultant providing legal services to several life sciences companies. From 2007 to 2014, Mr. Bucher served as Vice President, Corporate Legal Affairs and Secretary, and as the Corporate Compliance Officer, of Exelixis, Inc., a biopharmaceutical company. From 1991 to 2007, Mr. Bucher practiced as a corporate attorney at the international law firm Shearman & Sterling LLP, becoming a partner in 2001. Mr. Bucher holds a J.D. with distinction from Emory University School of Law and a B.A. in Biology from Colgate University.

Randal Hassler

Mr. Randal A. Hassler is Executive Vice President, Pharmaceutical Operations of the Company. Mr. Hassler has served as our Executive Senior Vice President of Pharmaceutical Operations since February 2018, and prior to that served as our Senior Vice President of Pharmaceutical Operations from August 2014 to February 2018. From 2008 to 2014, Mr. Hassler served in various leadership positions at Seattle Biomedical Research Institute, a non-profit infectious disease research institute, most recently as Chief Operating Officer. From 1995 to 2007, he served in various leadership positions at Amgen Inc., a biopharmaceutical company, including Process Development, Quality Control, and Quality Assurance. From 1983 to 1995, Mr. Hassler served in a variety of research and development positions at Synergen Inc., a biotechnology company, which was acquired by Amgen in 1994. Mr. Hassler holds a B.S. in Microbiology from Indiana University and an M.S. in Microbiology from Colorado State University.

Nadia Dac

Ms. Nadia Dac is Chief Commercial Officer of the company. Ms. Dac has served as our Chief Commercial Officer since April 2019. From December 2014 to March 2019, she served as Vice President, Global Specialty Commercial Development at AbbVie, Inc., a biopharmaceutical company. Prior to AbbVie, Ms. Dac served as Sr. Vice President of Marketing at Auxillium Pharmaceuticals, Inc. from May 2013 to September 2014, when the company was acquired by Endo International plc. From 2009 to 2013, Ms. Dac held several roles of increasing responsibility at Novartis AG, including Global Vice President, Neuroscience Professional Relations prior to her role as Vice President, MS Franchise. She holds a B.S. in Marketing from Rutgers University.

Jeffrey Smith

Dr. Jeffrey T.L. Smith, M.D., is Managing Director of the Company., a subsidiary of the Company. Dr. Smith has served as our Managing Director of Alder Biopharmaceuticals Limited since March 2017. Dr. Smith previously served as our Senior Vice President, Translational Medicine from 2012 to March 2017 and in other senior management positions from April 2004 to 2012. From 1999 to 2004, Dr. Smith served as Senior Director of Medical Research for Celltech R&D, where he was responsible for planning and managing the CDP870 anti-TNF clinical trials for rheumatoid arthritis as well as several other key autoimmune clinical development programs. From 1997 to 1999, Dr. Smith served as Medical Director at Simbec Research Ltd., a contract research organization. From 1995 to 1997, Dr. Smith served as Head of Clinical Pharmacology at Hoechst Marion Roussel Ltd., a pharmaceutical company. From 1994 to 1995, Dr. Smith served as a Senior Clinical Physician at the Proctor and Gamble Company, a publicly-traded consumer products company, and from 1989 to 1994, he served as a Senior Research Physician in the clinical pharmacology department at Glaxo Research and Development Ltd., now a division of GlaxoSmithKline plc. Dr. Smith holds an M.D. from the University of London and is a Fellow of the Royal College of Physicians in London.

Paul Streck

Dr. Paul Streck M.D. is Chief Medical Officer of the Company. Dr. Streck has served as our Chief Medical Officer since January 2019. From June 2017 to January 2018, Dr. Streck served as Chief Medical Officer of Insmed Incorporated. From November 2015 to June 2017, Dr. Streck served as Vice President, Global Medical Specialty Franchise, Immuno-inflammation at GlaxoSmithKline plc. From November 2007 to November 2015, Dr. Streck held various positions at Shire Pharmaceuticals plc. Dr. Streck served as Group Vice President, Clinical Development/TA Lead (Hematology, Gastrointestinal, Internal Medicine) at Shire Pharmaceuticals from November 2013 to November 2015. Prior to that, Dr. Streck served as Global Head of Medical Affairs, Internal Medicine (November 2012 to December 2013), Product General Manager, Emerging Business Unit (November 2011 to November 2012), and Senior Director, Global Clinical Development (November 2007 to December 2012) at Shire Pharmaceuticals. From February 2006 to October 2007, Dr. Streck was Director of Marketing at AMGEN USA Inc. Dr. Streck holds an M.B.A. from the Duke University Fuqua School of Business, an M.D. from Jefferson Medical College, a D.M.D. from the Temple University School of Dentistry and a B.A. in chemistry from Rutgers University.

Paul Cleveland

Mr. Paul B. Cleveland is Director of the Company. Mr. Cleveland has served as a member of our Board of Directors since August 2015. Between March 2018 and June 2018, Mr. Cleveland served as our Interim President and Chief Executive Officer. Since October 2016, Mr. Cleveland has served as the Chairman of the board of directors of Adverum Biotechnologies, Inc., a biotechnology company. From October 2017 through June 2017, Mr. Cleveland served as Executive chairman of Adverum and from December 2015 to October 2016, he served as President and Chief Executive Officer of Adverum. From May 2015 to November 2015, Mr. Cleveland served as President and Chief Executive Officer at Celladon Corporation, a clinical-stage biotechnology company, and previously served as Celladon’s President and Chief Financial Officer since June 2014. From February 2013 to August 2013, Mr. Cleveland served as Executive Vice President, Corporate Strategy and Chief Financial Officer of Aragon Pharmaceuticals, Inc., a biotechnology company. From April 2011 to February 2013, Mr. Cleveland served as General Partner and Chief Operating Officer of Mohr Davidow Ventures, a venture capital firm. From January 2006 to February 2011, Mr. Cleveland served as Executive Vice President, Corporate Development and Chief Financial Officer of Affymax, Inc., a biopharmaceutical company. From April 2004 to December 2005, he served as a managing director at Integrated Finance, Ltd., an investment bank. From September 1996 to April 2003, Mr. Cleveland served as a managing director at investment bank J.P. Morgan Chase and Co. and a predecessor firm, Hambrecht & Quist. From January 1993 to September 1996, Mr. Cleveland was a partner at Cooley LLP, from December 1988 to December 1992, he was a corporate attorney at Sidley Austin LLP and from September 1981 to November 1988. Mr. Cleveland received an A.B. from Washington University in St. Louis and a J.D. from Northwestern University School of Law.

Paul Carter

Mr. Paul Rutherford Carter is Independent Director of the Company. Mr. Carter has served as a member of our Board of Directors since September 2015. From April 2006 to August 2016, Mr. Carter served in various roles at Gilead Sciences, Inc., a research based biopharmaceutical company, most recently serving as Executive Vice President, Commercial Operations. Prior to joining Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline and its legacy companies. During his time with GlaxoSmithKline, Mr. Carter gained increasing levels of senior experience as General Manager in Europe and later as a Regional Head of the International Business in Asia. Mr. Carter currently serves on the board of directors of Hutchison China Meditech Ltd, a biopharmaceutical company. Mr. Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the United Kingdom’s Chartered Institute of Management Accountants.

Jeremy Green

Mr. Jeremy C. Green is Independent Director of the Company. Mr. Green has served as a member of our Board of Directors since April 2018. Since 2007, Mr. Green has served as the Founder and Portfolio Manager of Redmile Group, LLC, a San Francisco-based investment firm that focuses on the healthcare sector. Prior to founding Redmile Group, LLC, Mr. Green served as Co-Founder and Director of Research at Steeple Capital L.P., and as an analyst at Andor Capital Management, L.L.C. Prior to that, Mr. Green served as a Managing Director at Citigroup Inc. and Head of the European Healthcare Research Team covering medical technology, biotech and healthcare services. Mr. Green holds a B.A. in Natural Science—Biological Sciences and an M.A. from the University of Oxford.

A. Bruce Montgomery

Dr. A. Bruce Montgomery, M.D., is Independent Director of the Company. Dr. Montgomery has served as a member of our Board of Directors since October 2010. Since March 2017, Dr. Montgomery has served as the Chief Executive Officer of Avalyn Pharma Inc., a pharmaceutical company. In 2010, Dr. Montgomery founded Cardeas Pharma Corporation, a biotechnology company, where he served as Chief Executive Officer and a member of the board of directors from 2010 to December 2016. In 2001, he founded Corus Pharma, Inc., a biotechnology company, and served as its Chief Executive Officer from 2001 through its acquisition in 2006 by Gilead Sciences, Inc. He continued on at Gilead post-acquisition until 2010 and served as Senior Vice President and Head of Respiratory Therapeutics, where he successfully led the approval of Cayston (aztreonam) as a treatment for cystic fibrosis patients. From 1993 to 2000, Dr. Montgomery held positions within the research and development group of PathoGenesis Corporation, a biotechnology company. From 1989 to 1993, Dr. Montgomery worked at Genentech, Inc., a biotechnology company. Dr. Montgomery currently serves on the board of directors of Xencor Inc. Dr. Montgomery holds an M.D. and a B.S. in Chemistry from the University of Washington.

Heather Preston

Dr. Heather Preston, M.D., is Independent Director of the Company. Dr. Preston has served as a member of our Board of Directors since December 2007. Since July 2018, Dr. Preston has served as managing partner at Pivotal BioVenture Partners and as a Senior Advisor of TPG Biotech, a biotechnology venture capital firm. Dr. Preston was previously a Partner and Managing Director at TPG Biotech, from 2005 to July 2018. Prior to joining TPG Biotech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at J.P. Morgan Partners, LLC, a private equity firm. Prior to that, she was an Entrepreneur-in-Residence at New Enterprise Associates, a venture capital firm, and was a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co in New York. Dr. Preston currently serves on the board of directors of Entasis Therapeutics Holdings, Inc., Oxford BioMedica plc, Otonomy, Inc. and numerous private companies. Dr. Preston holds an M.D. from the University of Oxford and a B.S. in Biochemistry from the University of London.

Clay Siegall

Dr. Clay B. Siegall, Ph.D., is Independent Director of the Company. Dr. Siegall has served as a member of our Board of Directors since November 2005. In 1998, Dr. Siegall co-founded Seattle Genetics, Inc., a biotechnology company, and currently serves as its President, Chief Executive Officer and Chairman of the Board of Directors. From 1991 to 1997, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, National Institutes of Health from 1988 to 1991. In addition to Seattle Genetics and Alder, Dr. Siegall currently serves on the board of directors of Ultragenyx Pharmaceutical Inc. and he previously served on the board of directors of Mirna Therapeutics, Inc. from January 2013 to December 2016. Dr. Siegall holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

Wendy Yarno

Ms. Wendy L. Yarno is Independent Director of the Company. Ms. Yarno has served as a member of our Board of Directors since March 2017. Ms. Yarno retired in September 2008 from Merck & Co., Inc. following a 26-year career there in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer before she retired. Prior to this role, she served as General Manager, Cardiovascular/Metabolic United States Business Unit, where she had P&L responsibility for Merck’s largest therapeutic area, and as Senior Vice President, Human Resources. From September 2010 through September 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds. Ms. Yarno currently serves on the board of directors of MyoKardia, Inc., a biopharmaceutical company, Aratana Therapeutics, Inc., a pet therapeutics company, Global Blood Therapeutics, Inc. and Inovio Pharmaceuticals, Inc. Ms. Yarno previously served as member of the board of directors of St. Jude Medical, Inc., a medical device company, from April 2002 until January 2017 when St. Jude Medical was acquired by Abbott Laboratories, Medivation, Inc., a biopharmaceutical company, from April 2013 until September 2016 when Medivation was acquired by Pfizer Inc., and Durata Therapeutics, Inc., a pharmaceutical company, from August 2014 until November 2014 when Durata was acquired by Actavis plc. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A. from Temple University.

Basic Compensation

Name Fiscal Year Total

Robert Azelby

10,130,800

Carlos Campoy

1,844,370

Erin Lavelle

3,680,390

James Bucher

1,961,540

Randal Hassler

4,217,190

Nadia Dac

--

Jeffrey Smith

2,060,180

Paul Streck

--

Paul Cleveland

1,168,770

Paul Carter

215,590

Jeremy Green

463,759

A. Bruce Montgomery

208,122

Heather Preston

48,394

Clay Siegall

213,124

Wendy Yarno

210,729
As Of  31 Dec 2018